August 2026: Imperial Brands to Cut Thousands of Jobs in Major US and European Restructuring
Imperial Brands is preparing to eliminate thousands of jobs across its operations in the United States and Europe, marking one of the company’s largest workforce reductions in recent years as it maneuvers to protect operating margins and fund a multi-year transition toward next-generation nicotine products.
According to sources familiar with the decision, the upcoming headcount cuts target operational overhead in core Western markets where traditional combustible cigarette volumes have continued to face steady, long-term declines. The cost-cutting drive is structured to free up capital for the company’s expanding portfolio of non-combustible products, including Pulze heated tobacco line, Skruf/ZONE oral nicotine pouches, and blu vapor products.
The sweeping restructuring follows recent operational adjustments across the company’s European supply chain, including plans to shutter its manufacturing facility in Langenhagen, Germany, which directly affected 640 employees. Financial disclosures from earlier this year revealed that Imperial Brands had already expanded its restructuring provisions to £223 million, underscoring the scale of its organizational realignment.
Major international tobacco producers have increasingly turned to broad efficiency programs to offset shrinking cigarette markets and finance transformation to smoke-free products. Imperial Brands is expected to outline specific target metrics regarding annual cost savings and one-off execution charges in its upcoming financial updates.
July 2026: Kenneth Dart Further Reduces Stake in Imperial Brands
Spring Mountain Investments, the Cayman Islands–based investment vehicle of Kenneth Dart, has reduced its stake in Imperial Brands after selling 8.7 million shares. The transaction lowers its ownership from 3.99% to 2.91%. Following the sale, Spring Mountain retains 22.4 million shares, valued at approximately £628 million at the time of writing. At its peak in early 2024, the firm held a 7.04% stake, reflecting a continued and gradual reduction in its investment.
As of June 30, 2026, Imperial Brands’ issued share capital comprised 832.7 million shares, including 62.6 million (7.5%) treasury shares. As a result, the company has 770.1 million voting rights.
May 2026: Imperial Brands acquires Black Buffalo
Imperial Brands has announced the acquisition of Black Buffalo, a modern oral nicotine business, expanding its presence in the U.S. oral category. Founded in 2015, Black Buffalo produces tobacco-alternative long cut and pouch products aimed at adult users of traditional moist smokeless tobacco (MST). Its products are designed to closely replicate the taste, ritual, and branding of conventional MST, while removing tobacco leaf and stem. The company uses a proprietary “farm-to-can” process developed over several years of research and development. Its products are manufactured in North Carolina using U.S.-grown barn-cured leafy greens, with added pharmaceutical-grade nicotine and food-grade flavourings.
Black Buffalo’s offering is positioned as distinct from Imperial’s existing U.S. nicotine pouch range under the Zone brand. Imperial stated that combining Black Buffalo’s established brand and product differentiation with its commercial infrastructure and sales capabilities would broaden choice for adult consumers seeking non-combustible oral nicotine products.
The deal has an initial consideration of $150 million, with an additional deferred payment linked to performance over three years and other conditions. Imperial described the transaction as consistent with its capital allocation approach, focused on bolt-on acquisitions, alongside its ongoing multi-year share buyback programme. The Black Buffalo team will join Imperial following completion of the transaction.
April 2026: Kenneth Dart Further Reduces Stake in Imperial Brands
Spring Mountain Investments, the Cayman Islands–based investment vehicle of Kenneth Dart, has reduced its holding in Imperial Brands following the sale of 6.56 million shares. The transaction lowers its ownership from 4.80% to 3.99%. Following the disposal, Spring Mountain retains 31.1 million shares, valued at approximately £861 million at the time of writing. At its peak in early 2024, the firm held a 7.04% stake, indicating a continued and gradual reduction in its position.
March 2026: Kenneth Dart Further Reduces Stake in Imperial Brands
Spring Mountain Investments, the Cayman Islands–based investment vehicle of Kenneth Dart, has reduced its holding in Imperial Brands following the sale of 10.6 million shares. The transaction lowers its ownership from 5.86% to 4.80%. Following the disposal, Spring Mountain retains 37.66 million shares, valued at approximately £1.17 billion at the time of writing. At its peak in early 2024, the firm held a 7.04% stake, indicating a continued and gradual reduction in its position.
February 2026: Imperial Brands Partners with Capgemini to Accelerate Transformation and Deliver 2030 Strategy
Imperial Brands entered a long-term, global strategic partnership with business and technology firm Capgemini to accelerate its transformation into a stronger challenger business and support its 2030 strategic goals. The collaboration will help Imperial become more agile, data-led and efficient, bringing Capgemini’s full suite of technology services – including advanced data insights and agentic AI – to enhance consumer understanding, sales capabilities and innovation. As part of the partnership, Imperial is consulting on transferring teams from its finance & procurement hub in Krakow and its global supply chain centre in Warsaw to Capgemini. Further details on the company’s transformation plans will be shared with its half-year results in May 2026. Executive leaders from both companies emphasized their commitment to deepening capabilities and driving growth toward Imperial’s strategic objectives.
January 2026: Imperial Brands Appoints a New Chairman of the Board
Imperial Brands announced the appointment of John Rishton as a Non-Executive Director and Chair Designate. John will join the Board as Non-Executive Director and Chair Designate on July 13, 2026. He will succeed Thérèse Esperdy as Chair on December 1, 2026, at which time Thérèse will retire from the Board. Thérèse was appointed to the Imperial Brands Board in July 2016 and became Senior Independent Director in May 2019 before being appointed Chair in January 2020. Under the UK Corporate Governance Code, she had reached the “comply or explain” nine-year tenure point from her date of appointment to the Board in 2025.
John is currently chair of Informa PLC (appointed in 2016) and a non-executive director of Diageo PLC. He served as chair of Serco Group PLC between 2021 and 2025 and was a non-executive director of Unilever PLC and Allied Domecq PLC. John’s previous executive positions include chief executive of Rolls-Royce Group PLC from 2011 to 2015 (having been a non-executive director since 2007), chief financial officer and then chief executive and president of Royal Ahold NV and chief financial officer of British Airways PLC.
December 2025: Imperial Brands participates in the Morgan Stanley Global Consumer & Retail Conference
“Focused value creation and accelerated NGP scale” was the central theme at the Morgan Stanley Global Consumer & Retail Conference. Imperial Brands outlined a clear, two-pillar investment case built on a cash-generative combustible business and a fast-growing next-generation products (NGP) platform, underpinned by a consumer-centric operating model and a major people overhaul. Management expects tobacco to deliver low single-digit net revenue growth of 1%–2% over the next five years, supported by pricing power, while NGPs will grow at double-digit rates and materially accelerate group performance. The company is targeting 3%–5% operating profit growth and annual cash generation of around £2.2–3.0 billion, which together underpin a high-single-digit EPS growth ambition and an evergreen share buyback programme through 2030. Imperial noted it has returned more than £11 billion to shareholders over the past five years.
In combustible segment, management emphasised pricing ahead of volume as the core value lever. Volume decline moderated from -7% in 2023 to -4% in 2024 and to about -2% in 2025, with H2 2025 running close to flat. Nevertheless, Imperial cautioned against extrapolating short-term improvements and pointed to the longer-term pre-COVID volume trend as the more reasonable frame. Imperial underlined that roughly £50 of every £100 of revenue flows straight to profit in the current margin structure, giving significant cash conversion and scope to extract value through pricing and mix in core markets (notably the U.S., Germany and Spain). Africa was singled out as a high-quality cluster delivering c.10% of group operating profit, with combustible volume growth in parts of the region approaching 4% and attractive upside from focused brand and route-to-market investment.
NGPs are the strategic growth engine and Imperial described a differentiated, consumer-led approach: selective market entry where the category and routes-to-market are established, product innovation tailored to local consumer preferences, and disciplined resource allocation. The company reiterated double-digit NGP growth guidance for 2026 and its mid-term plan, citing category growth assumptions of c.3% for vapes, c.10% for modern oral and c.13% for heated tobacco. Key programme metrics include Zone in the U.S. (launched ~18 months ago, now in >100,000 stores, c.2.8% national share and c.4% within the footprint), and gross-margin convergence targets where mature markets approach industry benchmarks: vape markets such as the UK, Spain, Germany and Greece near 50% gross margin, heated tobacco (Czech, Italy, Greece) near 45%, and very mature nicotine-pouch markets in the Nordics and Austria around 70%.
In terms of transformation, capital allocation and risk, the new leadership emphasised both investment and efficiency. The group will invest c.£600 million to build a more agile, data-led organisation and expects to deliver £320–330 million of annualised savings by 2030 through manufacturing excellence, simplification (including the announced Langenhagen factory exit) and technology-led sales improvements such as AI sales coaches. Imperial expects to invest £300-350 million of capital expenditure per year, maintain net debt/EBITDA in a 2.0x–2.5x range (current leverage ~2.0x), target annual free cash flow of about £2.2–3.0 billion, sustain a progressive dividend and return surplus capital via meaningful buybacks while preserving headroom for M&A and contingency. Management’s principal upside that the market may be underestimating is the durability of combustible cash generation combined with the path to a profitable, scaled NGP business; the chief derailers would be an unforeseeable systemic crisis or regulatory outcomes materially more adverse than their base stress tests anticipate.
Download Imperial Brands MS GCR Conference transcript
September 2025: Imperial Brands participates in the Barclays Global Consumer Staples Conference
Imperial Brands’ leadership transition was the central theme at the Barclays Global Consumer Staples Conference. The outgoing CEO reflected on his five-year tenure, during which Imperial’s share price rose substantially from around £12 at the lows of 2020 to above £30. He emphasized that the company now stands on a stronger footing, with growth achieved both in its traditional tobacco operations and in next-generation products (NGPs). The incoming CEO committed to continue steering the business, with a strategic focus on extracting further value from combustibles while scaling NGPs at a double-digit growth rate over the next five years. The Company is targeting ongoing EBIT growth of 3–5% through 2030, underpinned by capital discipline and cost savings.
Imperial confirmed that its NGP strategy remains primarily organic but will be complemented by selective bolt-on acquisitions. The business has already achieved double-digit net revenue growth in reduced-risk products over the past two years, gaining market share across all three categories. In the U.S., which accounts for roughly one-third of Imperial’s revenues, cigarettes represent 80% of the portfolio and cigars 20%. The Company highlighted its Zone nicotine pouch brand, launched in February 2024, which captured a 3% share in modern oral nicotine within 18 months in the U.S. While competitors seek shortcuts around regulatory approval, Imperial stressed its adherence to compliance, noting that innovation within the rules is a competitive strength. Its premium Backwoods cigar brand also remains resilient, with demand normalizing after COVID-driven spikes but still showing positive long-term trends.
Germany, Imperial’s second-largest market contributing about 17% of EBIT, has turned from being a persistent share loser into a stabilizing force. After more than a decade of decline, Imperial has reported share gains in Germany and expects to maintain momentum through investments in brand equity and salesforce capabilities. The U.K., once a larger contributor but now high single-digit in the profit pool, faces heavy excise taxation and mid-teen volume declines. Nevertheless, Imperial recently surpassed 10% market share in vapes, reflecting strong performance in pod-based systems after disposable vapes were banned. Australia, now just 4% of EBIT, continues to present regulatory challenges, though Imperial has sustained profitability there, while Africa and the Middle East are emerging as attractive longer-term opportunities. Separately, with the global modern oral nicotine (“nicotine pouch”) revenue at around £100 million and market presence in 10 countries, Imperial aims to expand further but in a disciplined, market-driven way.
On capital allocation, Imperial reiterated its commitment to shareholder returns. It plans to generate nearly £3 billion in free cash flow by 2030, with high-single to low-double-digit EPS growth driven by a combination of EBIT growth, buybacks, and efficiency gains. The Company has embedded £320 million in annualized savings into its long-term guidance, earmarking the funds to strengthen its NGP portfolio, brand investments, and consumer insights. Imperial also reaffirmed its “evergreen” five-year buyback program and stressed that excess capital, not just free cash flow, would be returned to shareholders. Leverage is targeted at 2x net debt/EBITDA, with scope for further flexibility as earnings expand.
Finally, Imperial addressed investor concerns about valuation and listing location. While U.K. equities trade at a discount to U.S. peers, Imperial sees no need to move its listing across the Atlantic. Instead, the Company has leaned on its growing ADR program to capture U.S. investor interest. The leadership transition marks a new chapter, with the incoming CEO focused on sustaining shareholder value creation through a blend of steady cash generation from combustibles and disciplined investment in growth categories.
Download the event transcript: Imperial Brands – Barclays Global Consumer Staples Conference
August 2025: FDA denies marketing for blu disposable vape
The U.S. Food and Drug Administration (FDA) issued a marketing denial order (MDO) for blu Classic Tobacco 2.4% disposable vape manufactured by Fontem LLC, a U.S. subsidiary of Imperial Brands. Consequently, Imperial Brands is no longer permitted to market or distribute the product in the United States; however, Imperial Brands may submit a new application for the product.
After reviewing the Imperial’s premarket tobacco product application (PMTA), FDA determined that the application lacked sufficient evidence to demonstrate that permitting marketing of the product would be appropriate for the protection of the public health, the standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act. According to the FDA, Imperial did not provide sufficient evidence that adults who smoke will completely switch to the new product or significantly reduce their cigarette consumption. Instead, Imperial’s evidence suggests that people will likely use this product in addition to cigarettes, potentially exposing them to higher levels of toxicants than exclusive cigarette use. FDA stated that, in general, long periods of using both e-cigarettes and cigarettes – often referred to as “dual use” – can result in harms to health similar to, or in addition to, the harms from exclusive use of cigarettes.
FDA also highlighted that it has authorized e-cigarettes currently on the market that had evidence that adults who smoke will completely switch to those products or significantly reduce their cigarette consumption and are potentially less harmful.
June 2025: Capital Group ups its stake in Imperial Brands to 13%
Los Angeles-based The Capital Group increased its stake in Imperial Brands from 12.05% to 13.03% – now holding 106.2 million ordinary Imperial Brands shares. The Capital Group is the largest shareholder of both British American Tobacco (BAT) and Imperial Brands. The investment management firm, with more than US$2.8 trillion assets under management, has been steadily increasing its tobacco holdings – upping its BAT stake from 13% in July 2024 to 18.1% in June 2025.
June 2025: Imperial Brands releases the results from two new behavioural studies
Imperial Brands releases the results from two new behavioural studies on its vape products, blu Bar and blu 2.0, to demonstrate how adult smokers use these products in their daily lives to reduce, or even to replace, cigarettes. The studies tracked adult smokers who had no plans to quit at the study outset, and found that around 29% of the participants shifted from smoking cigarettes to vaping blu after one week. Vaping blu led to 30% decrease in the number cigarettes smoked per day. Fruit and mint flavours were identified to be a crucial part of the transition from smoking cigarettes to vaping blu – in the blu 2.0 study, almost 29% of the participants exclusively used fruit flavours. In the blu Bar study, 60% of the participants stated that they planned to purchase blu in the future because they liked the flavours – which underlines the impact of flavours in encouraging the participants to continue vaping and not return to cigarettes. The longer term follow-up – around six months later – revealed that between a third and 40% of paritcipants had either significantly reduced smoking cigarettes, or even stopped completely. Previously, Imperial Brands conducted a similar study on the heated tobacco platform, PULZE device & iD sticks.
June 2025: Imperial Brands presents at the 2025 dbAccess Global Consumer Conference
At the 2025 Deutsche Bank dbAccess Global Consumer Conference, Imperial Brands reflected on the transformational progress over the past five years and laid out the Company’s forward-looking strategy. Imperial highlighted the company’s evolution from being the number one share donor in its top five markets in 2020 to holding and even gaining market share – up over 40 basis points in the last five years – mainly thanks to the strategic investments in brand equity and sales capabilities. The Company now plays a competitive role in the next-generation products (NGP) space, with credible offerings in all three major categories – vaping, heated tobacco, and modern oral. Innovation pace has accelerated, as evidenced by the launch of Pulse 3.0 for heated tobacco and the Zone brand in the U.S. modern oral market, which has already captured a 5% share in its footprint. Zone, launched in February 2025, differentiates itself through a more “Nordic-style” moist oral nicotine pouch with higher nicotine content. The company’s challenger mindset and cultural transformation were emphasized repeatedly, with employee engagement scores reflecting growing internal pride.
Top-5 Market Overview: In the U.S. – the company’s largest market – brand investments and salesforce expansion have led to consistent gains in market share and profit. The company has maintained a competitive edge through full price-tier brand coverage, crucial in a price-sensitive, volatile market. Moreover, Imperial increased its U.S. sales force by 40%, significantly boosting outlet coverage and quality. Germany, previously a laggard, held share in FY24 for the first time in years, increasing by 2 basis points at year-end and by over 60 basis points in H1 FY25. The turnaround was attributed to long-term underinvestment being corrected with brand investments and salesforce improvements, albeit slower due to labor regulations. The UK, representing 8% of total business, faced challenges from inflation-linked excise taxes. Despite this, Imperial managed to pass all excise increases to consumers and even took further pricing action. In Spain – the company’s third-largest market by volume – years of pricing constraints due to affordability concerns are easing. Imperial opted to lead price increases, temporarily sacrificing market share for value. Australia remains a challenging environment, with 30-40% of combustibles and 99% of NGP estimated to be illicit. Nonetheless, Imperial has maintained strong value extraction from the market. Regulatory enforcement and potential normalization in legal NGP sales – now permitted without prescription in pharmacies – offer future upside.
The company’s five-year strategy includes a significant focus on profitability in NGP. Losses in this segment have been consistently reduced, and breakeven is expected through scale-driven growth rather than cutbacks. NGP sales have grown double digits over the past two years, with continued momentum projected. The company believes vaping, heated tobacco, and modern oral can all deliver attractive gross margins once scaled, aligning with Imperial’s goal of building a “meaningful and profitable” NGP business. Operational efficiency is another pillar, with a multi-year ERP rollout replacing 60 disparate systems, aiming to unlock value through standardized processes, improved data usage, and scalable decision-making. Financially, Imperial has committed to a 3-5% AOP (adjusted operating profit) CAGR and a high single-digit EPS CAGR, supported by disciplined capital allocation and an “evergreen” share buyback program extended for the next five years. This commitment is based on stable cash flows from combustibles and ongoing investments in growth areas. Regulation, while ever-present, is not expected to disrupt strategy. In the U.S., the administration’s pro-business stance and emerging state-level enforcement – like Louisiana’s legally allowed vape list – support Imperial’s position. The Company remains vigilant but confident that the regulatory environment is stable and manageable.
In terms of CEO transition, Imperial underlined continuity and evolution rather than disruption, promising to build on existing foundations and unlock further value. The 2030 Strategy underscores the importance of maintaining agility, consumer focus, and disciplined execution. It aims to grow NGP profitably, improve operational leverage, and drive shareholder returns through buybacks & dividends to create long-term value. Overall, Imperial aspires to sustain its positioning as the industry challenger.
The key message Imperial Brands tried to deliver at the Deutsche Bank Global Consumer Conference:
“Continuity, confidence, and readiness to scale further heights, with strong positioning to deliver on the 2030 Strategy amid changing consumer preferences, regulatory landscapes, and industry competition”
June 2025: Voting Rights & Capital
As of May 30, 2025, Imperial Brands’ issued share capital consists of 883,855,872 ordinary shares of 10p each with voting rights. The Company holds 65,589,137 shares (7.42% of the issued capital) in treasury. Therefore, the total number of voting rights in the Company is 818,266,735.
May 2025: Imperial Brands announces the CEO succession plan
Imperial Brands announced that Stefan Bomhard will retire as Chief Executive Officer (CEO) and he will be succeeded by Lukas Paravicini, currently Chief Financial Officer (CFO) on October 1, 2025. Bomhard will continue to serve on the Imperial Brands Board until December 31, 2025 and be available until May 2026 to support the transition. Murray McGowan, currently Chief Strategy and Development Officer, will become CFO and a member of the Board on October 1, 2025.
Bomhard was appointed as CEO in July 2020. During his tenure as CEO, Imperial Brands strengthened the tobacco operations, built a refreshed platform for next-generation products, and delivered significant returns to shareholders. Paravicini was appointed as CFO in May 2021 and McGowan joined Imperial Brands in July 2020.
Since July 2020, Imperial Brands shares increased 91% and total shareholder return reached 136% (including dividends). Annual dividend paid by Imperial Brands increased 11.4% from £1.377 to £1.5343 per share.
March 2025: Imperial Brands announces the Long-Term Incentive Plan
Imperial Brands announced the performance measures and targets for the FY25 Long-Term Incentive Plan (LTIP) – the equity-based incentive program for the company executives and top-level managers. The LTIP has 4 financial (EPS growth, return on capital, FCF and TSR; 90% in total weight) and 2 ESG (carbon emission and energy consumption reduction; 10% in total weight) targets as listed below.
Imperial’s Remuneration Committee retains the discretion under the rules of the LTIP to adjust up or down the number of shares to be vested, taking into account a number of factors including personal or corporate performance and circumstances that were unforeseen at the date of grant.
March 2025: Spring Mountain’s stake in Imperial Brands increases marginally due to the share count reduction
Kenneth Dart’s Spring Mountain Investments’ stake in Imperial Brands increased marginally from 6.97% to 7.00% due to the share count reduction. Dart announced his first significant stake (2.8%) in Imperial Brands in April 2021 and is also the second largest shareholder in BAT with a 10.4% stake.
Los Angeles-based, The Capital Group is Imperial Brands’ largest shareholder with a 11.92% stake. Both San Francisco-based, Dodge & Cox and Bermuda-based, FIL Limited have a 4.98% stake in Imperial Brands.
December 2024: [2ONE ZONE Lawsuit] A preliminary injunction is issued against Imperial’s ZONE nicotine pouches in the US
2ONE Labs is granted a favorable Preliminary Injunction (PI) order in the ongoing trademark dispute with Imperial Brands’ Zone nicotine pouches sold in the USA1. As a result of the Court Order, Imperial are prohibited from engaging in any future sales of the Zone nicotine pouches bearing the Bullseye Mark or any confusingly similar colourable imitation or mark. Thereby, Imperial won’t be able to ship Zone nicotine pouches to trade partners in the USA without a major design modification.
The preliminary ruling supports 2ONE’s claim that the launch of Zone pouches in late 2023 created trademark confusion from which Imperial Brands benefited by growing its sales on the back of 2ONE’s brand name, imagery, adult consumer awareness and established goodwill. “Strong Zone launch performance in the US” was a point of focus in Imperial’s FY24 results; being present in 42k stores in 12 US metropolitan areas, Zone quickly reached 1.6% US national SoM (4.3% SoM in footprint).
September 2024: Key notes from the Barclays Global Consumer Staples Conference
Imperial Brands Management notes that
– Imperial made progress in closing the capability gaps (in terms of strategy, people, process, etc.) over the past 4 years
– operating profit growth is accelerating towards mid-single digit (as set out in the Phase II of the 5-year strategic plan) and an EBIT growth of 6% is possible in FY25
– the defining feature of Imperial in the US (which positions it for EBIT growth there) is its broad portfolio which can reach consumers at every price point in a market where downtrading is significant – in contrast to Altria and BAT’s premium-skewed portfolios
– 9% annual volume decline in the US is not the new normal (a temporary phenomenon caused by the macroeconomic pressures and illicit disposable vapes)
– Japan Tobacco’s acquisition of Vector is unlikely to significantly change the market dynamics in the US (i.e. in the sense of threatening Imperial’s presence in the discount segment)
– US mass market cigar segment (20% of the US business) is returning to a more normal pattern (i.e. slower volume decline) after sharp post-Covid decline and COGS inflation passed over to the consumer (higher weight of leaf in COGS due to the premium leaves used)
– leaf inflation is 14%-15% in FY24 (recall: COGS is ~30% of the net revenue and leaf is ~30% of the COGS) and they expect (no deflation, but) lower leaf inflation next year
– Imperial’s NGP strategy to be present in all 3 categories (heated tobacco, vape, nicotine pouch) and provide a competitive offer when there is a clear picture of emerging consumer preference for a category in a given market
– although there is an opportunity to return more than 100% of the cash-flow to the shareholders in the upcoming years, (for the time being) Imperial prefers to maintain some headroom to weather unexpected events
– their priority is to create shareholder value irrespective of where the stock is listed and moving the primary listing to the US is not being considered – despite admitting the valuation multiple gap (between the US and UK stocks) and US being the single biggest market for Imperial (with ~35% weight in revenue).
June 2023: Imperial Brands acquires a range of nicotine pouch products from TJP Labs
Imperial acquires a range of 14 nicotine pouch variants from TJP Labs in order to facilitate its entry into the US modern oral market2
– TJP pouches (claimed to) perform strongly in consumer testing
– £65Mn plus a deferred payment based on 5-year sales volumes
– Products to be re-launched in 2024 under a new brand
– TJP Labs will continue to manufacture the oral nicotine pouches under contract for ITG Brands
In Jan 2023, PMTA submission for TJP Labs’ L!X brand was accepted for review by the US FDA3.
The Imperial’s acquisition announcement doesn’t contains any further insights on the business case & the due diligence conducted:
(1) The rationale behind the strategy change: from “no interest in entering the US nicotine pouch market” to “paying £65Mn plus bonus for 14 nicotine pouch variants to facilitate the entry”
(2) The assessment of the probability of 14 TJP Labs pouches receiving (PMTA) marketing order
(3) The benefit of having TJP Labs products in addition to the Zone X & Skruf
(4) How accretive the investment is (US nicotine pouch market growth, Imperial’s intended SoS and the investment needed to reach the aforementioned SoS)
References:
- https://www.globenewswire.com/news-release/2024/12/23/3001123/0/en/Preliminary-Injunction-Issued-in-favor-of-2ONE-Nicotine-Pouches-Against-Zone-Pouches-Imperial-are-enjoined-from-engaging-in-any-future-sales-of-the-Zone-product-bearing-the-Bullsey.html ↩︎
- https://www.imperialbrandsplc.com/media/key-announcements/2023/imperial-acquires-us-nicotine-pouches-range-from-tjp ↩︎
- https://tjplabs.com/tjp_labs_press_releases/fda-acceptance-for-premarket ↩︎
